Generic name:immune globulin-ifas (intravenous route) [ i-MUNE-GLOB-ue-lin-- ifas ]
Drug class:Immune globulins
Medically reviewed by Drugs.com. Last updated on May 16, 2022.
Warning: Thrombosis, Renal Dysfunction, and Acute Renal FailureThrombosis may occur with immune globulin intravenous (IGIV) products, including immune globulin-ifas. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Immune globulin-ifas does not contain sucrose.For patients at risk of thrombosis, renal dysfunction, or renal failure, administer immune globulin-ifas at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity .
Commonly used brand name(s)
In the U.S.
- Panzyga
Available Dosage Forms:
- Solution
Therapeutic Class: Immune Serum
Uses for Panzyga
Immune globulin-ifas injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral immunodeficiency (PI), including congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and other severe combined immune system problems. It is also used to raise your platelet counts to control or prevent bleeding in patients with chronic immune thrombocytopenia (ITP). This medicine is also used to improve nerve and muscle problems in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
This medicine is to be given only by or under the supervision of your do..
